Udayavni Special

Antibiotic use can increase nerve damage risk: Study


Team Udayavani, May 15, 2019, 4:23 PM IST

Image for Representation

London: A common class of antibiotics — used to treat respiratory and urinary tract infections — may increase a patient’s risk of suffering a serious and potentially permanent form of nerve damage by almost 50 per cent.

Scientists from the University of Dundee in the UK looked at a database of 1.3 million adults issued one or more prescriptions of fluoroquinolone or amoxicillin-clavulanate antibiotics with no diagnosis of peripheral neuropathy at the outset of treatment.

Peripheral neuropathy has long been recognised as a potential side effect of fluoroquinolone antibiotics — that are commonly used to treat a variety of illnesses such as respiratory and urinary tract infections.

The study, published in the journal JAMA Neurology, found that current use of systemic fluoroquinolone antibiotics appeared to increase the risk of peripheral neuropathy by 47 per cent, causing an additional 2.4 cases per 10,000 patients per year of treatment.

A person prescribed with amoxicillin-clavulanate were not significantly more likely to experience peripheral neuropathy.

The risk was higher for men and rose with age and with the length of fluoroquinolone treatment. A peripheral neuropathy diagnosis remained more likely to be diagnosed for up to six months after the fluoroquinolone prescription.

Older men, the group most likely to experience the condition after taking a 28-day course of fluoroquinolones, were said to have a one in 34,000 chance of doing so.

While the absolute risk of a peripheral neuropathy diagnosis remained low, the findings should still be considered as one of the different potential side effects before prescribing antibiotics, researchers said.

“The safety of fluoroquinolone antibiotics has received a lot of attention regarding their potential to cause long-term side effects in some people,” said Daniel Morales, from the University of Dundee.

“One of these is peripheral neuropathy where nerves, most commonly affecting the lower limbs, can be affected, leading to numbness, pain, or problems with balance,” Morales said in a statement.

“Fluoroquinolones are effective antibiotics but health care professionals should recognise that peripheral neuropathy may rarely occur following fluoroquinolone therapy,” he said.

“We observed that treatment with fluoroquinolones could increase the risk of peripheral neuropathy by around 50 per cent and that this risk may last for up to six months following treatment,” he said.

Top News

IISc completes ICU-grade ventilator prototype

PM launches portal to help, hand-hold MSMEs

Udupi: Highest single day spike of 73 new COVID-19 cases

70% of people want Modi to be PM for another term: BSY

Violence against healthcare personnel unacceptable: PM

PM Modi praises state govt’s efforts in handling COVID crisis

Govt’s locust control policy focuses on chemical spray alone: Farm expert

Related Articles More

Potential Covid-19 vaccine generates immunity in Monkeys: Study

Tuberculosis Vaccine may be helpful in fighting Covid-19: Study

40 million children aged 13 to 15 years using tobacco products globally: WHO

4 Indian Covid-19 vaccines to begin human trials soon

Healthium MedTech launches anti-microbial gloves

MUST WATCH

Tragedy and chaos: Former MIA director recalls Mangalore Air Crash

Lockdown relaxation: Long queues outside liquor stores in Mangaluru

Indian Coast Guard thank Covid-19 warriors

#WeFeed – Feeding stray animals during lockdown!

Mysuru-origin doctor honoured with parade for her service in treating COVID-19 patients in US

Latest Additions

Enhancement of MSME’s turnover limit to help exporters

IISc completes ICU-grade ventilator prototype

PM launches portal to help, hand-hold MSMEs

COVID-19 impact: Top 100 Indian firms likely to lose $25B of brand value

Udupi: DC warns of strict action on traffic rules violations

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.